Julie Clark, MD
Chief Medical Officer
Dr. Julie Christine Clark joined 4DMT in 2025 and serves as Chief Medical Officer. She previously served as Senior Vice President of Clinical Research and Development. She is a distinguished physician-scientist and clinical development executive with over two decades of industry experience driving innovation in ophthalmology, particularly in retina therapeutics. Dr. Clark has built a career defined by scientific rigor, strategic leadership, and a deep commitment to improving patient outcomes through cutting-edge therapies.
Her career spans a diverse array of roles across clinical development, medical affairs, and commercial strategy, with a particular focus on biologics, oligonucleotides and gene therapy. Dr. Clark has led the design and execution of global pivotal trials, overseen pharmacovigilance and safety monitoring programs, and managed cross-functional teams through global regulatory submissions, label negotiations, and payer reimbursement strategies.
Prior to her current role, Dr. Clark held senior leadership positions at Novartis Pharmaceuticals, Adverum Biotechnologies, Iveric Bio (now part of Astellas) and Opthea. Her tenure is marked by significant contributions to retina drug development including US and global approvals for transformative therapies, including Eylea®, Jetrea®, Beovu® and Izervay®.
Her academic foundation includes a Doctor of Medicine from Wake Forest University School of Medicine, where she was inducted into Alpha Omega Alpha, and a Master of Science in Biotechnology from Johns Hopkins University.